TrialBlood2017

Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT.

Mohammad Abu Zaid et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.